Claims for Patent: 9,777,277

Summary for Patent: 9,777,277

Title:	Organic small hairpin RNAs
Abstract:	Disclosed are improved shRNA molecules, termed \"organic shRNA\" (OshRNA), that incorporate certain structural features that increase the likelihood that the desired guide strand is produced while reducing accumulation of passenger strands that might contribute to off-target effects. Also provided herein are nucleic acids encoding OshRNAs, kits, cells, and transgenic animals comprising such nucleic acids, as well as methods of making and using OshRNAs and/or nucleic acids encoding OshRNAs.
Inventor(s):	Lau; Nelson (Watertown, MA), Zeng; Mei (Newton, MA), Paradis; Suzanne (Lexington, MA), Kuzirian; Marissa (Waltham, MA)
Assignee:	Brandeis University (Waltham, MA)
Application Number:	14/892,629
Patent Claims:	1. An isolated nucleic acid molecule, comprising a nucleic acid sequence encoding an organic shRNA (OshRNA) sequence comprising, in 5' to 3' order, a 5' constant stem sequence, a guide sequence, a constant stem loop, a passenger sequence, and a 3' constant stem sequence; wherein: the guide sequence is a nucleic acid sequence of 22 nucleotides in length that is the reverse complement of a target nucleic acid sequence; and the passenger sequence is a nucleic acid sequence that is the reverse complement of the guide sequence but wherein the complementary nucleotides at positions 11 and 12 are absent and wherein a non-complementing nucleotide is at position 19. 2. The isolated nucleic acid molecule of claim 1, wherein the 5' constant stem sequence, the constant stem loop, and the 3' constant stem sequence are a miR-30a 5' constant stem sequence, a miR-30a constant stem loop, and a miR-30a 3' constant stem sequence, respectively. 3. The isolated nucleic acid molecule of claim 2, wherein the miR-30a 5' constant stem sequence, the miR-30a constant stem loop, and the miR-30a 3' constant stem sequence are from human miR-30a , mouse miR-30a, or Xenopus miR-30a. 4. The isolated nucleic acid molecule of claim 1, wherein at least 3 of the 4 nucleotides at the 5' end of the guide sequence are A, T, or U. 5. The isolated nucleic acid molecule of claim 1, wherein at least 3 of the 4 nucleotides at the 3' end of the guide sequence are G or C. 6. The isolated nucleic acid molecule of claim 1, wherein the target nucleic acid sequence is in a 3' untranslated region of a target mRNA. 7. The isolated nucleic acid molecule of claim 1, wherein the target nucleic acid sequence is in an open reading frame of a target mRNA. 8. The isolated nucleic acid molecule of claim 1, wherein the isolated nucleic acid molecule is a single-stranded RNA molecule. 9. The isolated nucleic acid of claim 1, wherein the isolated nucleic acid molecule is a double-stranded DNA molecule. 10. The isolated nucleic acid molecule of claim 9, wherein the isolated nucleic acid molecule is an expression vector. 11. The isolated nucleic acid molecule of claim 10, wherein the expression vector expresses an RNA molecule that comprises the OshRNA sequence. 12. The isolated nucleic acid molecule of claim 11, wherein the expressed RNA molecule is an mRNA molecule and the OshRNA sequence is located in an intron or a 3' untranslated region of the mRNA molecule. 13. A cell, comprising a nucleic acid molecule, comprising a nucleic acid sequence encoding organic shRNA (OshRNA) comprising, in 5' to 3' order, a 5' constant stem sequence, a guide sequence, a constant stem loop, a passenger sequence, and a 3' constant stem sequence; wherein: the guide sequence is a nucleic acid sequence of 22 nucleotides in length that is the reverse complement of a target nucleic acid sequence; and the passenger sequence is a nucleic acid sequence that is the reverse complement of the guide sequence but wherein the complementary nucleotides at positions 11 and 12 are absent and wherein a non-complementing nucleotide is at position 19. 14. The cell of claim 13, wherein the 5' constant stem sequence, the constant stem loop, and the 3' constant stem sequence are a miR-30a 5' constant stem sequence, a miR-30a constant stem loop, and a miR-30a 3' constant stem sequence, respectively. 15. The cell of claim 14, wherein the miR-30a 5' constant stem sequence, the miR-30a constant stem loop, and the miR-30a 3' constant stem sequence are from human miR-30a, mouse miR-30a, or Xenopus miR-30a. 16. The cell of claim 13, wherein at least 3 of the 4 nucleotides at the 5' end of the guide sequence are A, T, or U. 17. The cell of claim 13, wherein at least 3 of the 4 nucleotides at the 3' end of the guide sequence are G or C. 18. The cell of claim 13, wherein the target nucleic acid sequence is in a 3' untranslated region of a target mRNA. 19. The cell of claim 13, wherein the target nucleic acid sequence is in an open reading frame of a target mRNA. 20. The cell of claim 13, wherein the nucleic acid molecule is a single-stranded RNA molecule. 21. The cell of claim 13, wherein the nucleic acid molecule is a double-stranded DNA molecule. 22. The cell of claim 21, wherein the nucleic acid molecule is an expression vector. 23. The cell of claim 22, wherein the expression vector expresses an RNA molecule that comprises the OshRNA sequence. 24. The cell of claim 23, wherein the expressed RNA molecule is an mRNA molecule and the OshRNA sequence is located in an intron or a 3' untranslated region of the mRNA molecule. 25. The cell of claim 21, wherein the nucleic acid molecule is integrated into the genomic DNA of the cell. 26. A transgenic non-human animal, comprising a nucleic acid molecule, comprising a nucleic acid sequence encoding organic shRNA (OshRNA) comprising, in 5' to 3' order, a 5' constant stem sequence, a guide sequence, a constant stem loop, a passenger sequence, and a 3' constant stem sequence; wherein: the guide sequence is a nucleic acid sequence of 22 nucleotides in length that is the reverse complement of a target nucleic acid sequence; and the passenger sequence is a nucleic acid sequence that is the reverse complement of the guide sequence but wherein the complementary nucleotides at positions 11 and 12 are absent and wherein a non-complementing nucleotide is at position 19. 27. The transgenic non-human animal of claim 26, wherein the 5' constant stem sequence, the constant stem loop, and the 3' constant stem sequence are a miR-30a 5' constant stem sequence, a miR-30a constant stem loop, and a miR-30a 3' constant stem sequence, respectively. 28. The transgenic non-human animal of claim 27, wherein the miR-30a 5' constant stem sequence, the miR-30a constant stem loop, and the miR-30a 3' constant stem sequence are from human miR-30a, mouse miR-30a, or Xenopus miR-30a. 29. The transgenic non-human animal of claim 26, wherein at least 3 of the 4 nucleotides at the 5' end of the guide sequence are A, T, or U. 30. The transgenic non-human animal of claim 26, wherein at least 3 of the 4 nucleotides at the 3' end of the guide sequence are G or C. 31. The transgenic non-human animal of claim 26, wherein the target nucleic acid sequence is in a 3' untranslated region of a target mRNA. 32. The transgenic non-human animal of claim 26, wherein the target nucleic acid sequence is in an open reading frame of a target mRNA. 33. The transgenic non-human animal of claim 26, wherein the animal is a mouse. 34. The transgenic non-human animal of claim 26, wherein the nucleic acid molecule is integrated into the genome of the animal. 35. The transgenic non-human animal of claim 34, wherein the animal expresses an RNA molecule that comprises the OshRNA sequence. 36. The transgenic non-human animal of claim 35, wherein the expressed RNA molecule is an mRNA molecule and the OshRNA sequence is located in an intron or a 3' untranslated region of the mRNA molecule. 37. A method of inhibiting expression of a target nucleic acid in a cell, comprising contacting the cell with an isolated nucleic acid molecule of claim 1, wherein the target nucleic acid molecule comprises the target nucleic acid sequence. 38. The method of claim 37, wherein the isolated nucleic acid molecule is a single-stranded RNA molecule. 39. The method of claim 37, wherein the isolated nucleic acid molecule is a double-stranded DNA molecule. 40. The method of claim 39, wherein the isolated nucleic acid molecule is an expression vector. 41. The method of claim 40, wherein the expression vector expresses an RNA molecule that comprises the OshRNA sequence. 42. The method of claim 41, wherein the expressed RNA molecule is an mRNA molecule and the OshRNA sequence is located in an intron or a 3' untranslated region of the mRNA molecule. 43. The method of claim 37, wherein the cell is a human cell. 44. The method of claim 37, wherein the method is performed in vitro. 45. The method of claim 37, wherein the method is performed in vivo. 46. A kit, comprising an isolated nucleic acid molecule of claim 1. 47. The kit of claim 46, wherein the isolated nucleic acid molecule is a single-stranded RNA molecule. 48. The kit of claim 46, wherein the isolated nucleic acid molecule is a double-stranded DNA molecule. 49. The kit of claim 48, wherein the isolated nucleic acid molecule is an expression vector. 50. The kit of claim 49, wherein the expression vector expresses an RNA molecule that comprises the OshRNA sequence. 51. The kit of claim 50, wherein the expressed RNA molecule is an mRNA molecule and the OshRNA sequence is located in an intron or a 3' untranslated region of the mRNA molecule. 52. An OshRNA library, comprising at least 10 different isolated nucleic acid molecules of claim 1. 53. The library of claim 52, comprising at least 100 different isolated nucleic acid molecules of claim 1. 54. The library of claim 52, wherein the isolated nucleic acid molecules are single-stranded RNA molecules. 55. The library of claim 52, wherein the isolated nucleic acid molecules are double-stranded DNA molecules. 56. The library of claim 55, wherein the isolated nucleic acid molecules are expression vectors. 57. The library of claim 56, wherein the expression vectors express RNA molecules that comprise the OshRNA sequence. 58. The library of claim 57, wherein the expressed RNA molecules are mRNA molecules and the OshRNA sequence is located in an intron or a 3' untranslated region of the mRNA molecules.

Details for Patent 9,777,277

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132	06/04/1986		2033-05-31
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	For Injection	103132			2033-05-31
Merck Sharp & Dohme Corp.	INTRON A	interferon alfa-2b	Injection	103132			2033-05-31